Conditions: Parkinson's Disease Psychosis
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 39
Healthy volunteers: no

Brief summary:
This is an open-label extension study to assess the long-term safety and tolerability of pimavanserin (ACP-103) in subjects with Parkinson's Disease Psychosis (PDP).

Detailed description:

Arms:
arm 1: Tablets taken once daily by mouth at 20, 40, or 60 mg doses

Interventions: intervention 1: pimavanserin tartrate (ACP-103)
Intervention descriptions: intervention 1: Tablets taken once daily by mouth at 20, 40, or 60 mg doses

Protocol document: